Marie Hudson

Marie Hudson

Auto-generated profile, based on publicly available information

Marie Hudson

M. Hudson, MD, MPH, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2011 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
WDWilliam G Dixon
William G Dixon
SSSamy Suissa
Samy Suissa
MHMarie Hudson
Marie Hudson
Introduction: Infection is a major cause of morbidity and mortality in patients with rheumatoid arthritis (RA). The objective of this study was to perform a systematic review and meta-analysis of the effect of glucocorticoid (GC) therapy on the risk of infection in patients with RA. Methods: A systematic review was conducted by using MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials database to January 2010 to identify studies among populations of patients with RA that reported a comparison of infection incidence between patients treated with GC therapy and patients not exposed to GC therapy. Results: In total, 21 randomised controlled trials (RCTs) and 42 observational studies were included. In the RCTs, GC therapy was not associated with a risk of infection (relative risk (RR), 0.97 (95% CI, 0.69, 1.36)). Small numbers of events in the RCTs meant that a clinically important increased or decreased risk could not be ruled out. The observational studies generated a RR of 1.67 (1.49, 1.87), although significant heterogeneity was present. The increased risk (and heterogeneity) persisted when analyses were stratified by varying definitions of exposure, outcome, and adjustment for confounders. A positive dose-response effect was seen. Conclusions: Whereas observational studies suggested an increased risk of infection with GC therapy, RCTs suggested no increased risk. Inconsistent reporting of safety outcomes in the RCTs, as well as marked heterogeneity, probable residual confounding, and publication bias in the observational studies, limits the opportunity for a definitive conclusion. Clinicians should remain vigilant for infection in patients with RA treated with GC therapy.

30 July 2009 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
MHMarie Hudson
Marie Hudson
BTBrett D. Thombs
Brett D. Thombs
RSRussell Steele
Russell Steele
PPPantelis Panopalis
Pantelis Panopalis
ENEvan Newton
Evan Newton
CGCanadian Scleroderma Research Group
Canadian Scleroderma Research Group
Objective: A number of studies (all n <200) have assessed health‐related quality of life (HRQOL) in patients with systemic sclerosis (SSc), but no systematic review of the effect of SSc on HRQOL has been done. The objective of this study was to systematically review the literature on HRQOL in SSc measured using the Medical Outcomes Trust Short Form 36 (SF‐36).Methods: A comprehensive search was conducted in August 2007 using Medline, CINAHL, and EMBase to identify original research studies reporting SF‐36 scores of SSc patients. Selected studies were reviewed and characteristics of the study samples and SF‐36 data were extracted. Bayesian meta‐analysis and meta‐regression were performed to obtain pooled estimates of SF‐36 physical component summary (PCS) and mental component summary (MCS) scores for all patients as well as by limited and diffuse disease status.Results: Twelve data sets with a total of 1,127 SSc patients were included in the systematic review. HRQOL was impaired in patients with SSc, with pooled SF‐36 PCS scores being more than 1 SD below the general population (38.3; 95% credible interval [95% CI] 35.2, 41.5) and pooled SF‐36 MCS scores being ∼0.5 SDs below the general population (46.6; 95% CI 44.2, 49.1). SF‐36 PCS scores were 3.5 points (95% CI −1.0, 8.0) lower in patients with diffuse compared with limited disease.Conclusion: This study provides robust evidence of the presence and magnitude of impairment in HRQOL in patients with SSc. Although the impairment appears greater in physical health, mental health impairment is also reported.

3 May 2016 in Genome Biology
Verified
Journal Article
Open access
PDF file
KMKevin McGregor
Kevin McGregor
SBSasha Bernatsky
Sasha Bernatsky
ICInes Colmegna
Ines Colmegna
MHMarie Hudson
Marie Hudson
TPTomi Pastinen
Tomi Pastinen
CGCelia M.T. Greenwood
Celia M.T. Greenwood
Many different methods exist to adjust for variability in cell-type mixture proportions when analyzing DNA methylation studies. Here we present the result of an extensive simulation study, built on cell-separated DNA methylation profiles from Illumina Infinium 450K methylation data, to compare the performance of eight methods including the most commonly used approaches. We designed a rich multi-layered simulation containing a set of probes with true associations with either binary or continuous phenotypes, confounding by cell type, variability in means and standard deviations for population parameters, additional variability at the level of an individual cell-type-specific sample, and variability in the mixture proportions across samples. Performance varied quite substantially across methods and simulations. In particular, the number of false positives was sometimes unrealistically high, indicating limited ability to discriminate the true signals from those appearing significant through confounding. Methods that filtered probes had consequently poor power. QQ plots of p values across all tested probes showed that adjustments did not always improve the distribution. The same methods were used to examine associations between smoking and methylation data from a case–control study of colorectal cancer, and we also explored the effect of cell-type adjustments on associations between rheumatoid arthritis cases and controls. We recommend surrogate variable analysis for cell-type mixture adjustment since performance was stable under all our simulated scenarios.

27 March 2012 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
RSRussell Steele
Russell Steele
MHMarie Hudson
Marie Hudson
ELErnest Lo
Ernest Lo
MBMurray Baron
Murray Baron
TGThe Canadian Scleroderma Research Group
The Canadian Scleroderma Research Group

1 April 2014 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
MHMarie Hudson
Marie Hudson
MBMurray Baron
Murray Baron
STSolène Tatibouet
Solène Tatibouet
DFDaniel E. Furst
Daniel E. Furst
DKDinesh Khanna
Dinesh Khanna

6 March 2012 in Arthritis Research & Therapy
Verified
Journal Article
Open access
MHMarie Hudson
Marie Hudson
JPJanet Pope
Janet Pope
MMMichael Mahler
Michael Mahler
STSolène Tatibouet
Solène Tatibouet
RSRussell Steele
Russell Steele
MFMarvin Jacob Fritzler
Marvin Jacob Fritzler
Introduction: Autoantibodies to Ro52 recently identified as TRIM21 are among the most common autoantibodies in systemic autoimmune rheumatic diseases, but their clinical association remains poorly understood. We undertook this study to determine the clinical and serologic associations of anti-Ro52/TRIM21 antibodies in patients with systemic sclerosis (SSc). Methods: Detailed clinical data and sera from 963 patients with SSc enrolled in a multicenter cohort study were collected and entered into a central database. Antibodies to Ro52/TRIM21 and other autoantibodies were detected with an addressable laser-bead immunoassay and different enzyme-linked immunosorbent assay (ELISA) systems. Associations between anti-Ro52/TRIM21 antibodies and clinical and other serologic manifestations of SSc were investigated. Results: Anti-Ro52/TRIM21 antibodies were present in 20% of SSc patients and overlapped with other main SSc-related antibodies, including anti-centromere (by immunofluorescence and centromere protein (CENP)-A and CENP-B ELISA), anti-topoisomerase I, anti-RNA polymerase III, and anti-Pm/Scl antibodies. Anti-Ro52/TRIM21 antibodies were strongly associated with interstitial lung disease (odds ratio (OR), 1.53; 95% confidence interval (CI), 1.11 to 2.12; P = 0.0091) and overlap syndrome (OR, 2.06; 95% CI, 1.01 to 4.19; P = 0.0059). Conclusions: Anti-Ro52/TRIM21 antibodies were the second most common autoantibodies in this SSc cohort. In SSc, anti-Ro52/TRIM21 antibodies may be a marker of interstitial lung disease and overlap syndrome.